ABOUT TRK FUSION CANCER AND TESTING
Understanding TRK fusion cancer
TRK fusion cancer can occur in both adults and children. The location of a tumor can vary from person to person, but the cause is the same: an NTRK gene fusion. So having TRK fusion cancer doesn’t change your original diagnosis, it just explains the cause of it.
What genomic testing can tell you about your cancer
Genomic testing may or may not have already been done on your cancer. It’s important that you speak to your doctor about it. Genomic testing may reveal the cause of your cancer so your doctor has more information when deciding which treatment is right for you.
If your doctor has
prescribed VITRAKVI®
Your doctor has tested your cancer and found that it is caused by a fusion of the NTRK gene
You’ve been matched with a treatment specifically for your TRK fusion cancer
If you and your doctor are
considering potential treatments
You may want to learn whether a fusion of the NTRK gene is causing your cancer
Talk to your doctor about genomic testing to find out if VITRAKVI
could be right for you
What is VITRAKVI?
VITRAKVI is a prescription medicine that is used to treat adults and children with solid tumors (cancer) that:
are caused by certain abnormal NTRK genes and
have spread or if surgery to remove their cancer is likely to cause severe complications, and
there is no acceptable treatment option or the cancer grew or spread on other treatment.
Your healthcare provider will perform a test to make sure that VITRAKVI is right for you.
It is not known if VITRAKVI is safe and effective in children younger than 28 days of age.
VITRAKVI was approved through a faster FDA review process based on the percentage of patients whose tumor size shrank or disappeared after treatment and how long that response lasted. There are ongoing studies to confirm the benefit of VITRAKVI for this use.
Your healthcare provider will perform a test to make sure that VITRAKVI is right for you.
It is not known if VITRAKVI is safe and effective in children younger than 28 days of age.
VITRAKVI was approved through a faster FDA review process based on the percentage
of patients whose tumor size shrank or disappeared after treatment and how long that response lasted. There are ongoing studies to confirm the benefit of VITRAKVI for this use.
Some questions you can ask your doctor about genomic testing:
“I would tell other patients that, if you have the opportunity to have genomic testing done, go for it.”
Kayley, mother of Ashton, a TRK fusion cancer patient
